Cite
sj-pdf-16-tmj-10.1177_03008916221077144 – Supplemental material for Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis
MLA
Turco, Fabio, et al. Sj-Pdf-16-Tmj-10.1177_03008916221077144 – Supplemental Material for Role of Radium-223 Discontinuation Due to Adverse Events in Castration-Resistant Prostate Cancer Patients. A Retrospective Monocentric Analysis. Jan. 2022. EBSCOhost, https://doi.org/10.25384/sage.19501759.v1.
APA
Turco, F., Tucci, M., Angusti, T., Parente, A., Di Stefano, R. F., Urban, S., Pisano, C., Samuelly, A., Audisio, A., Audisio, M., Parlagreco, E., Ungaro, A., Scagliotti, G. V., Di Maio, M., & Buttigliero, C. (2022). sj-pdf-16-tmj-10.1177_03008916221077144 – Supplemental material for Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis. https://doi.org/10.25384/sage.19501759.v1
Chicago
Turco, Fabio, Marcello Tucci, Tiziana Angusti, Antonella Parente, Rosario Francesco Di Stefano, Susanna Urban, Chiara Pisano, et al. 2022. “Sj-Pdf-16-Tmj-10.1177_03008916221077144 – Supplemental Material for Role of Radium-223 Discontinuation Due to Adverse Events in Castration-Resistant Prostate Cancer Patients. A Retrospective Monocentric Analysis,” January. doi:10.25384/sage.19501759.v1.